ArticleMolecular pathology : MP2000
Frequent loss of heterozygosity on chromosome 5 in non-small cell lung carcinoma.
Article in Molecular pathology : MP, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 48 citations in OpenAlex.
- 12q Amplification Characterizes a Distinctive Salivary Gland Tumor with Bizarre Myoepithelial Atypia.Head and neck pathology · 2025Article
- NPM1 promotes nasopharyngeal carcinoma metastasis and stemness by recruiting Mdm2 to induce the ubiquitination-mediated degradation of p53.American journal of cancer research · 2023Article
- A Forward Genetic Approach to Mapping aG3 (Bethesda, Md.) · 2020Article
- ZCCHC10 suppresses lung cancer progression and cisplatin resistance by attenuating MDM2-mediated p53 ubiquitination and degradation.Cell death & disease · 2019Article
- c-Myc targeted regulators of cell metabolism in a transgenic mouse model of papillary lung adenocarcinoma.Oncotarget · 2016Article
- Copy number variation in archival melanoma biopsies versus benign melanocytic lesions.Cancer biomarkers : section A of Disease markers · 2016Article
- GLTSCR2 is an upstream negative regulator of nucleophosmin in cervical cancer.Journal of cellular and molecular medicine · 2015Article
- Deregulated expression of Nucleophosmin 1 in gastric cancer and its clinicopathological implications.BMC gastroenterology · 2014Article
- LAS1L interacts with the mammalian Rix1 complex to regulate ribosome biogenesis.Molecular biology of the cell · 2012Article
- An extensive tumor array analysis supports tumor suppressive role for nucleophosmin in breast cancer.The American journal of pathology · 2011Article
- Article
- Cancer models, genomic instability and somatic cellular Darwinian evolution.Biology direct · 2010Review
- Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies.Cancer research · 2009Article
- A loss-of-function polymorphism in the propeptide domain of the LOX gene and breast cancer.Cancer research · 2009Article
- Allelic loss on chromosome 5q34 is associated with poor prognosis in hepatocellular carcinoma.Journal of cancer research and clinical oncology · 2008Article
- Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse.Blood · 2008Article
- Article
- Molecular characterisation of the pericentric inversion that distinguishes human chromosome 5 from the homologous chimpanzee chromosome.Human genetics · 2005Article
- Intracellular localization and domain organization of human TRIM41 proteins.Molecular biology reports · 2005Article
- BRCTx is a novel, highly conserved RAD18-interacting protein.Molecular and cellular biology · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsLoss of heterozygosity (LOH) at specific chromosomal regions strongly suggests the existence of tumour suppressor genes at the relevant segment. Frequent LOH on chromosome 5q has been reported in a wide variety of human tumours, including those of the lung. The aim of this study was to screen for LOH and to clarify the location of putative tumour suppressor genes on chromosome 5 implicated in the genesis and/or development of non-small cell lung carcinoma.
methodsThirty three patients with advanced non-small cell lung carcinoma were screened for LOH with a panel of 21 microsatellite DNA markers spanning the entire chromosome 5, using semi-automated fluorochrome based methodology.
resultsTwenty of the non-small cell lung carcinoma samples displayed LOH for one or more informative locus. LOH involving only 5q was found in 10 of 14 of the informative samples. Deletions involving 5p only were not present in the samples under study. There was no evidence of microsatellite instability in any of the analysed loci. These results indicate the presence of five distinct segments displaying high frequencies of deletion on chromosome 5, namely: 5q11.2-q12.2, 5q15 (D5S644 locus), 5q22.3-q23.1, 5q31.1, and 5q35.3. Eight of 14 samples had simultaneous interstitial deletions in at least two different regions. Moreover, concomitant deletion of three and four distinct regions was displayed in three of 14 and two of 14, respectively, of the informative samples.
conclusionAllelic deletion on chromosome 5 is a frequent event in patients with non-small cell lung carcinoma. These results suggest the involvement of these five regions, either independently or simultaneously, in both lung squamous cell carcinoma and lung adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.